The FDA has approved generic febuxostat 40 mg and 80 mg tablets, a generic version of Uloric, for the management of chronic hyperuricemia in adult patients with gout. The tablets will be manufactured at Lupin’s facility in India and are estimated to have an annual U.S. sales of $27 million. This announcement follows the FDA approval of ANI Pharmaceuticals’ generic version of Indocin oral suspension for the treatment of ankylosing spondylitis and other conditions.
Source link
FDA approves Uloric generic for chronic hyperuricemia management in gout
